Biomx Inc. (PHGE) Stock Price & Analysis

Biomx Inc. (PHGE) fell 10.01% to USD 0.68 as of June 10, 2026 at 01:01 UTC, according to Nexqual real-time market data.

PHGE last closed at USD 0.76; the session ranged USD 0.65–0.75 on volume of 262,528 shares. Market capitalization is $7.61M, with a 52-week range of USD 0.36–14.71 (ASE). Source: Nexqual, June 10, 2026 at 01:01 UTC.

Key Statistics (as of June 10, 2026 at 01:01 UTC)

Technical Analysis (PHGE)

Nexqual's technical model rates PHGE "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 01:01 UTC.

Analyst Ratings (PHGE)

Wall Street analysts rate PHGE "None", per Nexqual as of June 10, 2026 at 01:01 UTC.

Earnings (PHGE)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 01:01 UTC.

Financials & Fundamentals (PHGE)

Source: Nexqual, June 10, 2026 at 01:01 UTC.

Financial Health Score (PHGE)

Nexqual rates Biomx Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 01:01 UTC.

Ownership (PHGE)

Source: Nexqual, June 10, 2026 at 01:01 UTC.

Leadership (PHGE)

Biomx Inc. is led by Michael Oster (age 53), CEO & Director, per Nexqual as of June 10, 2026 at 01:01 UTC.

Major Backers & Investors (PHGE)

Notable institutional backers of Biomx Inc. include Deerfield Management Company, L.P, Nantahala Capital Management, LLC, Ikarian Capital, LLC, according to Nexqual as of June 10, 2026 at 01:01 UTC.

Active Investors

Source: Nexqual, June 10, 2026 at 01:01 UTC.

From Biomx Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)

Key Strengths & Strategy (as disclosed to the SEC)

• Some foreign jurisdictions, including Europe and Japan, have analogous patent term extension provisions, which allow for extension of the term of a patent that covers a drug approved by the applicable foreign regulatory agency.    In the future, if and when our product candidates receive FDA approval, we expect to apply, if appropriate, for patent term extension on patents directed to those product candidates, their methods of use and/or methods of manufacture.
• However, there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions.   5     Trade Secrets and Know-How   In addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position.
• Biological Product Development Process   In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or the FDCA, and its implementing regulations under the FDCA, the Public Health Service Act, or the PHSA, and their implementing regulations.
• Any agency or judicial enforcement action could have a material adverse effect on us.   Certain of our current product candidates and future product candidates must be approved by the FDA through a Biologics License Application, or BLA, process before they may be legally marketed in the United States.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:01 UTC. This page is informational and not investment advice.